{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:45:21Z","timestamp":1788432321407,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12185-022-03330-y","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T16:42:59Z","timestamp":1648658579000},"page":"446-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis"],"prefix":"10.1007","volume":"116","author":[{"given":"Kumi","family":"Nakazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Shinozaki-Ushiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyoshi","family":"Hisamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"2","key":"3330_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"issue":"18","key":"3330_CR2","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2014-07-590398","volume":"125","author":"LJ Geskin","year":"2015","unstructured":"Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798\u2013805. https:\/\/doi.org\/10.1182\/blood-2014-07-590398.","journal-title":"Blood"},{"issue":"16","key":"3330_CR3","doi-asserted-by":"publisher","first-page":"adv00271","DOI":"10.2340\/00015555-3576","volume":"100","author":"I Lazaridou","year":"2020","unstructured":"Lazaridou I, Ram-Wolff C, Bouaziz JD, B\u00e9gon E, Battistella M, Rivet J, et al. Dupilumab treatment in two patients with cutaneous T-cell lymphomas. Acta Derm Venereol. 2020;100(16):adv00271. https:\/\/doi.org\/10.2340\/00015555-3576.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"3330_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.2340\/00015555-3208","volume":"99","author":"T Chiba","year":"2019","unstructured":"Chiba T, Nagai T, Osada SI, Manabe M. Diagnosis of mycosis fungoides following administration of dupilumab for misdiagnosed atopic dermatitis. Acta Derm Venereol. 2019;99(9):818\u20139. https:\/\/doi.org\/10.2340\/00015555-3208.","journal-title":"Acta Derm Venereol"},{"key":"3330_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","volume":"8","author":"K Russomanno","year":"2021","unstructured":"Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. JAAD Case Rep. 2021;8:83\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2020.12.010.","journal-title":"JAAD Case Rep"},{"key":"3330_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001875","author":"O Sokumbi","year":"2021","unstructured":"Sokumbi O, Shamim H, Davis M, Wetter D, Newman C, Comfere N. Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates. Am J Dermatopathol. 2021. https:\/\/doi.org\/10.1097\/DAD.0000000000001875.","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"3330_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","volume":"83","author":"ML Espinosa","year":"2020","unstructured":"Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020;83(1):197\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.050.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3330_CR8","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.12788\/cutis.0074","volume":"106","author":"LC Hollins","year":"2020","unstructured":"Hollins LC, Wirth P, Fulchiero GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis. 2020;106(2):E8\u201311. https:\/\/doi.org\/10.12788\/cutis.0074.","journal-title":"Cutis"},{"issue":"5","key":"3330_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1309\/W1GW-43HT-793U-F86R","volume":"121","author":"JR Brown","year":"2004","unstructured":"Brown JR, Weng AP, Freedman AS. Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. Am J Clin Pathol. 2004;121(5):701\u20138. https:\/\/doi.org\/10.1309\/W1GW-43HT-793U-F86R.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"3330_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/pin.12515","volume":"67","author":"A Ichikawa","year":"2017","unstructured":"Ichikawa A, Miyoshi H, Yamauchi T, Arakawa F, Kawano R, Muta H, et al. Composite lymphoma of peripheral T-cell lymphoma and Hodgkin lymphoma, mixed cellularity type; pathological and molecular analysis. Pathol Int. 2017;67(4):194\u2013201. https:\/\/doi.org\/10.1111\/pin.12515.","journal-title":"Pathol Int"},{"issue":"1","key":"3330_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/pai.0b013e31817c551f","volume":"17","author":"G Gualco","year":"2009","unstructured":"Gualco G, Chioato L, Van Den Berg A, Weiss LM, Bacchi CE. Composite lymphoma: EBV-positive classic Hodgkin lymphoma and peripheral T-cell lymphoma: a case report. Appl Immunohistochem Mol Morphol. 2009;17(1):72\u20136. https:\/\/doi.org\/10.1097\/pai.0b013e31817c551f.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"3330_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/jcp.2003.011882","volume":"57","author":"M Steinhoff","year":"2004","unstructured":"Steinhoff M, Hummel M, Assaf C, Anagnostopoulos I, Treudler R, Geilen CC, et al. Cutaneous T cell lymphoma and classic Hodgkin lymphoma of the B cell type within a single lymph node: composite lymphoma. J Clin Pathol. 2004;57(3):329\u201331. https:\/\/doi.org\/10.1136\/jcp.2003.011882.","journal-title":"J Clin Pathol"},{"issue":"3","key":"3330_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3109\/10428190109064615","volume":"42","author":"CS Bee","year":"2001","unstructured":"Bee CS, Blaise YP, Dunphy CH. Composite lymphoma of Hodgkin lymphoma and mycosis fungoides: previously undescribed in the same extracutaneous site. Leuk Lymphoma. 2001;42(3):543\u20139. https:\/\/doi.org\/10.3109\/10428190109064615.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"3330_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1515\/med-2020-0191","volume":"15","author":"W Gui","year":"2020","unstructured":"Gui W, Wang J, Ma L, Wang Y, Su L. Clinicopathological analysis of composite lymphoma: a two-case report and literature review. Open Med (Wars). 2020;15(1):654\u20138. https:\/\/doi.org\/10.1515\/med-2020-0191.","journal-title":"Open Med (Wars)"},{"issue":"1","key":"3330_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5858\/2006-130-107-CLHLAP","volume":"130","author":"S Sanchez","year":"2006","unstructured":"Sanchez S, Holmes H, Katabi N, Newman J, Domiatti-Saad R, Stone M, et al. Composite lymphocyte-rich Hodgkin lymphoma and peripheral T-cell lymphoma associated with Epstein-Barr virus: a case report and review of the literature. Arch Pathol Lab Med. 2006;130(1):107\u201312. https:\/\/doi.org\/10.5858\/2006-130-107-CLHLAP.","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"3330_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","volume":"135","author":"DJ Straus","year":"2020","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, et al. Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020;135(10):735\u201342. https:\/\/doi.org\/10.1182\/blood.2019003127.","journal-title":"Blood"},{"key":"3330_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-030-15138-6_4","volume":"421","author":"L Marcelis","year":"2019","unstructured":"Marcelis L, Tousseyn T, Sagaert X. MALT lymphoma as a model of chronic inflammation-induced gastric tumor development. Curr Top Microbiol Immunol. 2019;421:77\u2013106. https:\/\/doi.org\/10.1007\/978-3-030-15138-6_4.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"3330_CR18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ajh.25112","volume":"93","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(7):953\u201362. https:\/\/doi.org\/10.1002\/ajh.25112.","journal-title":"Am J Hematol"},{"issue":"10168","key":"3330_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"11","key":"3330_CR20","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/cup.13545","volume":"46","author":"A Goyal","year":"2019","unstructured":"Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol. 2019;46(11):823\u20139. https:\/\/doi.org\/10.1111\/cup.13545.","journal-title":"J Cutan Pathol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03330-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03330-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T16:09:17Z","timestamp":1661011757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03330-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3330"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03330-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. M. reports lecture fees from Kyowa Kirin Co., Ltd. and Takeda Pharmaceutical Co. Ltd. S. S. reports grants, lecture fees and consultation fees from Kyowa Kirin Co., grants and lecture fees from Takeda Pharmaceutical Co. Ltd., grants from Pfizer Japan Inc., grants from Nippon Kayaku Co. Ltd., and grants and lecture fees from Sanofi K.K. M.K. reports grants and lecture fees from Kyowa Kirin Co., grants and lecture fees from Takeda Pharmaceutical Co. Ltd., grants and lecture fees from Pfizer Japan Inc., and lecture fees from Sanofi K.K. For the remaining authors none were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}